Pfizer receives positive CHMP opinion for BESPONSA® (inotuzumab ozogamicin) for the treatment of relapsed or refractory acute lymphoblastic leukemia

25th May 2017 Uncategorised 0

Pfizer

More: Pfizer receives positive CHMP opinion for BESPONSA® (inotuzumab ozogamicin) for the treatment of relapsed or refractory acute lymphoblastic leukemia
Source: MDlinx